Frontlight ResearchEarly access
CompletedEarly phase 1
Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 24 people enrolled
- Started
- 25 Sept 2024
- Ended
- 25 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Colchicine
- Placebo
- Record updated
- 2 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age >= 18 years
- Diagnosis of peripheral artery disease
- Stated willingness to comply with all study procedures and availability for the duration of the study
Who cannot take part
- Use of colchicine or systemic anti-inflammatory medication (eg. tocilizumab) in the past 3 months
- Presence of medication with drug-drug interaction
- Recent (<14 days) systemic infection requiring hospitalization or ongoing treatment with antimicrobials
- History of uncontrolled diabetes or an A1C >10% prior to the baseline visit
- Allergy to colchicine
- Autoimmune/autoinflammatory disorders affecting blood vessels or with planned need for systemic anti-inflammatory medication
- History of persistent anemia, thrombocytopenia, or neutropenia requiring hematology/oncology treatment or felt to pose unacceptable risk to colchicine by the principal investigator
- History of CrCl < 30 mL/minute or eGFR < 30mL/minute or end-stage renal disease ESRD on dialysis
- History of liver disease or chronically-elevated (>3 months) ALT/AST > 3.0 x ULN
- Acute limb ischemia requiring emergent intervention
- Pregnant or lactating women
- Claustrophobia
Where in United States
- University of PennsylvaniaPhiladelphia, United States
About the trial
What the trial wants to find out
The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques. Researchers will compare patients receiving colchicine to patients receiving placebo to determine the effect of colchicine on the inflammatory state of atherosclerotic femoral arteries.
The 2 groups in the trial
- ColchicineTreatment being tested
Colchicine (0.6 mg oral daily for 4-weeks) will be the drug administered in this study.
- PlaceboPlacebo, for comparison
This arm is a matching placebo that will be administered in the same fashion as the experimental arm.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-Controlled Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
- Record updated
- 2 April 2026